Sugemalimab Achieves New Regulatory Milestone: European Commission Approves Stage Ⅲ NSCLC Indication

Ewopharma is pleased to report an important new regulatory milestone for sugemalimab licensed from Chinese partner CStone Pharmaceuticals. In late November 2025, the European Commission (EC) granted approval for a […]

Weiterlesen

Ewopharma AG Announces Exclusive Distribution Agreement for Cardiovascular Solutions in Bulgaria

Effective June 1, 2024, Ewopharma AG has the exclusive licence to distribute Translumina’s drug-eluting stents (DES) and Blue Medical’s drug-coated balloon (DCB) technologies in Bulgaria. The agreement includes two key […]

Weiterlesen

Ewopharma and CStone enter into a Strategic Partnership for Sugemalimab in Central Eastern Europe and Switzerland

Ewopharma announces today that it has entered into a strategic commercial collaboration with CStone Pharmaceuticals (“CStone”, HKEX: 2616), an innovationdriven biopharmaceutical company focused on the research and development of anti-cancer […]

Weiterlesen